Tim Geary obtained a BSc in Biology from the University of Notre Dame in 1975 and a PhD in Pharmacology (pharmacogenetics) in 1980 from the University of Michigan. After working on tropical parasitology, focused on malaria and onchocerciasis, at Michigan State University, he joined The Upjohn Company (Pharmacia – Pfizer-now Zoetis) in 1985. There he focused on the discovery and development of anthelmintics and became head of the parasite biology group. He remained at Pfizer until 2005, then joined the Institute of Parasitology at McGill University as Professor and Tier I Canada Research Chair. He served as Director of the Institute from 2007-2019, when he became Emeritus Professor. He became a Professor (20 % appointment) in the School of Biological Sciences at Queen’s University – Belfast in 2019. His work over the past 45+ years has focused on drug discovery and development for veterinary and human parasites, on the pharmacology of antiparasitic drugs and resistance to them, and on the molecular language of the host-parasite interface. Tim earned national and international funding to support his research and received many awards.  He has published > 250 peer-reviewed articles and book chapters, is on the editorial boards of 5 scientific journals and consults for many pharmaceutical, government and non-government organizations. He is a Past-President of the American Association of Veterinary Parasitologists and is a member of the Executive Committee of the World Association for the Advancement of Veterinary Parasitology.